Analyst Summary
- CNS Pharmaceuticals implemented a 1-for-50 reverse stock split effective February 21, 2025.
- The reverse stock split aims to increase the company’s per share trading price and meet Nasdaq’s minimum share price requirement.
- Post-split, the common stock will trade under the same symbol (CNSP) but with a new CUSIP number (18978H409).
- The number of outstanding shares was reduced from approximately 136.93 million to approximately 2.74 million.
- Authorized shares of common stock will remain at 300 million shares.
- Proportionate adjustments were made to outstanding stock options, restricted stock unit awards, and warrants.
Potential Implications
Stock Price
- The reverse stock split is primarily intended to increase the Company’s per share trading price.
- Compliance with Nasdaq’s listing requirement regarding minimum share price.